title: Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome.
authors.forename: H M
authors.initials: HM
authors.lastname: Robinson
authors.forename: Z J
authors.initials: ZJ
authors.lastname: Broadfield
authors.forename: K L
authors.initials: KL
authors.lastname: Cheung
authors.forename: L
authors.initials: L
authors.lastname: Harewood
authors.forename: R L
authors.initials: RL
authors.lastname: Harris
authors.forename: G R
authors.initials: GR
authors.lastname: Jalali
authors.forename: M
authors.initials: M
authors.lastname: Martineau
authors.forename: A V
authors.initials: AV
authors.lastname: Moorman
authors.forename: K E
authors.initials: KE
authors.lastname: Taylor
authors.forename: S
authors.initials: S
authors.lastname: Richards
authors.forename: C
authors.initials: C
authors.lastname: Mitchell
authors.forename: C J
authors.initials: CJ
authors.lastname: Harrison
mesh_terms: D002648:Child; D002675:Child, Preschool; D050676:Core Binding Factor Alpha 2 Subunit; D004268:DNA-Binding Proteins / Q000235:genetics*; D018572:Disease-Free Survival; D005784:Gene Amplification; D006801:Humans; D016130:Immunophenotyping; D009363:Neoplasm Proteins / Q000235:genetics; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics* / Q000401:mortality; D011379:Prognosis; D011518:Proto-Oncogene Proteins; D013997:Time Factors; D014157:Transcription Factors / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D050676:Core Binding Factor Alpha 2 Subunit; D004268:DNA-Binding Proteins; D009363:Neoplasm Proteins; D011518:Proto-Oncogene Proteins; C493728:RUNX1 protein, human; D014157:Transcription Factors